bioMérieux specialises in in vitro diagnostics with a strong focus on infectious disease and microbiology. Its systems and reagents support clinical labs in identifying pathogens, guiding antimicrobial therapy and monitoring outbreaks, and also serve industrial applications such as food safety and pharmaceutical quality control. Flagship platforms for automated culture, identification and rapid molecular panels are widely used in hospitals and reference laboratories worldwide.
| Year | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| 2022 | 3,589 | — | 452.4 | — |
| 2023 | 3,674.6 | 2.4% | 357.6 | -20.9% |
| 2024 | 3,979.9 | 8.3% | 432.2 | 20.9% |
| 2025 | 4,069.8 | 2.3% | 397.5 | -8% |
All markets — KeepWinning global stock screener
Other companies on Euronext Paris: Ayvens (AYV), Renault SA (RNO), Sodexo S.A. (SW), ABIVAX Société Anonyme (ABVX), Itissalat Al-Maghrib (IAM) S.A. (IAM), Gaztransport & Technigaz SA (GTT)